Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.

Accepted 2023-10-06 00:00:00 ET · period of report 2023-10-04 · accession 0001209191-23-052369 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-10-06	2023-10-04	RXRX	Gibson Christopher	CEO, Dir	M - OptEx	$2.48	+31.2K	902.5K	+4%	+$77.5K
D	2023-10-06	2023-10-04	RXRX	Gibson Christopher	CEO, Dir	S - Sale+OE	$7.21	-59.8K	842.7K	-7%	-$431.1K
D	2023-10-06	2023-10-04	RXRX	Gibson Christopher	CEO, Dir	M - OptEx	$0.00	-31.2K	468.8K	-6%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2023-10-04	M	A	31,250	$2.48	902,541	D	—	—
2	Common	Class A Common Stock	2023-10-04	S	D	59,794	$7.21	842,747	D	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $7.08 to $7.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3	Derivative	Stock Option (Right to Buy)	2023-10-04	M	D	31,250	$0.00	468,750	D	$2.48 · — to 2030-12-30	31,250 Class A Common Stock	(F5) The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.